Glioma Prognostic Panel Test
Short Name: Glioma Panel
Also known as: Glioma Genetic Panel, Brain Tumor Prognostic Panel, Glioma Molecular Profiling Test, IDH MGMT Glioma Panel
Glioma Prognostic Panel Test test available at DNA Labs India for ₹21,000. Uses Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS) on Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block samples. Results in Reports are typically available within 15 working days from the date the specimen is received and accepted at the laboratory. Reports submitted by Saturday 11:00 AM are prioritized in the processing queue.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The Glioma Prognostic Panel Test is performed to detect mutations in IDH1, IDH2, and assess MGMT promoter methylation status in glioma tumor tissue. These molecular markers are essential for determining the prognosis of glioma, predicting the tumor's response to standard chemotherapy (temozolomide), guiding treatment decisions, and stratifying patients for clinical trials. This test helps oncologists move beyond histological classification toward molecularly informed, personalized neuro-oncology care.
- Test Code
- 665
- CPT Code
- 81120
- ICD Code
- C71
- Price
- ₹21,000
- Sample Type
- Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block
- Result Time
- Reports are typically available within 15 working days from the date the specimen is received and accepted at the laboratory. Reports submitted by Saturday 11:00 AM are prioritized in the processing queue.
- Fasting Required
- No
- Method
- Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS)
Sample Collection
No special preparation is required from the patient. The FFPE tissue block is typically obtained from a prior biopsy or surgical resection procedure performed by the treating hospital or pathology lab.
Method: Tissue biopsy or surgical resection (processed into FFPE block by the referring pathology laboratory)
Laboratory Analysis
The FFPE tissue block is collected from the referring pathology laboratory or hospital. The block must contain at least 5% tumor tissue as confirmed by a pathologist. The specimen is sealed in a biohazard bag and shipped at room temperature to DNA Labs India.
Report Delivery
After the specimen reaches the laboratory, DNA is extracted from the FFPE tissue and subjected to PCR and Next Generation Sequencing for the analysis of IDH1, IDH2, and MGMT promoter methylation status. Results are typically available within 15 working days and delivered via the online portal, email, or WhatsApp.
Timeline: Reports are typically available within 15 working days from the date the specimen is received and accepted at the laboratory. Reports submitted by Saturday 11:00 AM are prioritized in the processing queue.
Patient Instructions
About This Test
Who Should Get This Test
The Glioma Prognostic Panel Test is performed to detect mutations in IDH1, IDH2, and assess MGMT promoter methylation status in glioma tumor tissue. These molecular markers are essential for determining the prognosis of glioma, predicting the tumor's response to standard chemotherapy (temozolomide), guiding treatment decisions, and stratifying patients for clinical trials. This test helps oncologists move beyond histological classification toward molecularly informed, personalized neuro-oncology care.
How to Prepare
- Submit a formalin-fixed paraffin-embedded (FFPE) tissue block from biopsy or surgical resection
- The block must contain a minimum of 5% tumor tissue, verified by a pathologist
- Ship the specimen at room temperature in a sealed biohazard specimen bag
- Include the patient's clinical history, prior histopathology report, and referring physician's details
- Ensure proper labeling with patient name, unique ID, and date of collection
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"Glioma molecular profiling has become a cornerstone of modern neuro-oncology. Identifying IDH1, IDH2, and MGMT promoter methylation status allows oncologists to stratify patients by prognosis and tailor treatment strategies, including decisions around temozolomide chemotherapy and immunotherapy eligibility. I recommend this panel for every newly diagnosed glioma patient to ensure optimal therapeutic planning."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- FFPE block with less than 5% tumor tissue
- Unlabeled or improperly labeled specimen
- Severely degraded or necrotic tissue with inadequate DNA yield
- Specimen received without accompanying clinical details or request form
Understanding Your Results
The tumor carries an IDH1 mutation, typically associated with lower-grade gliomas and secondary glioblastomas. This finding is generally associated with a more favorable prognosis compared to IDH wild-type tumors and may influence treatment decisions.
No IDH1 mutation was identified. IDH wild-type gliomas, particularly glioblastomas, are generally associated with a more aggressive clinical course. Additional molecular testing may be recommended.
The tumor carries an IDH2 mutation. Although less common than IDH1, IDH2 mutations carry similar prognostic implications and are considered in the WHO classification of diffuse gliomas.
No IDH2 mutation was identified. If IDH1 is also wild-type, the tumor may be classified as IDH wild-type, which can indicate a more aggressive subtype depending on histology and other markers.
The MGMT promoter is methylated, which silences the MGMT DNA repair enzyme. This is a favorable predictive marker indicating that the tumor is more likely to respond to temozolomide-based alkylating chemotherapy.
The MGMT promoter is unmethylated, meaning the MGMT repair enzyme remains active. Tumors with unmethylated MGMT are generally less responsive to temozolomide, and alternative treatment strategies may be considered.
Consult your oncologist or neuro-oncologist immediately if you have been diagnosed with a glioma, experience new or worsening neurological symptoms (persistent headaches, seizures, vision changes, weakness, or cognitive decline), or if your treating physician has recommended molecular profiling for treatment planning. The results of this test should always be interpreted by a qualified specialist in the context of your complete clinical and pathological profile.
Limitations
- ⚠This panel covers IDH1, IDH2, and MGMT markers only; it does not replace comprehensive genomic profiling for all actionable mutations
- ⚠Results are dependent on the quality and tumor cellularity of the submitted FFPE tissue
- ⚠False negatives may occur if tumor content is below the analytical sensitivity threshold
- ⚠This test is intended for use in conjunction with histopathological examination and clinical evaluation; it should not be used as a standalone diagnostic tool
- ⚠Newly emerging biomarkers beyond IDH and MGMT (e.g., TERT promoter, 1p/19q codeletion) may require additional testing
Risks & Considerations
- ●This test is performed on an already-collected tissue specimen and poses no additional physical risk to the patient
- ●As with any molecular test, there is a small possibility of false-negative or false-positive results due to technical limitations
- ●Emotional impact of results: patients should discuss findings with a qualified oncologist or genetic counselor to understand implications
Interfering Factors
- ●Insufficient tumor content in the FFPE block (must have at least 5% tumor tissue)
- ●Poor tissue fixation or over-fixation in formalin may degrade DNA quality
- ●Extensive tumor necrosis may reduce viable DNA yield
- ●Contamination during sample collection or processing
Compare With Similar Tests
| Test | Glioma Prognostic Panel Test | IDH1 R132H Immunohistochemistry (IHC) | MGMT Promoter Methylation (Standalone) | Comprehensive Genomic Profiling (CGP) for Brain Tumors |
|---|---|---|---|---|
| Comparison | Glioma Prognostic Panel Test | IHC is a simpler, lower-cost screening test that detects only the most common IDH1 R132H mutation. The Glioma Prognostic Panel uses PCR and NGS to detect a broader range of IDH1 and IDH2 mutations, providing more comprehensive molecular characterization. | A standalone MGMT methylation test evaluates only one marker. The Glioma Prognostic Panel includes MGMT along with IDH1 and IDH2 analysis, offering a more complete prognostic and predictive profile in a single test. | CGP panels analyze hundreds of genes and may include TERT, 1p/19q codeletion, TP53, ATRX, and more. The Glioma Prognostic Panel is a focused, cost-effective panel targeting the three most clinically impactful markers for initial glioma workup. |
Frequently Asked Questions
What is the Glioma Prognostic Panel Test?
What sample is required for this test?
What is the cost of the Glioma Prognostic Panel Test at DNA Labs India?
How long does it take to get the results?
What do IDH1 and IDH2 mutations mean in glioma?
What does MGMT promoter methylation indicate?
Is fasting required before this test?
Is this test covered by insurance?
Who should take the Glioma Prognostic Panel Test?
Can this test be used to diagnose glioma?
What technologies are used to perform this test?
Does DNA Labs India offer home sample collection for this test?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.